A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties

Biochemical Pharmacology

Volumn 85, Issue 11, 2013, Pages 1655-1662

  Bhat, Vikas K ^a   Kerr, Barry D ^a   Flatt, Peter R ^a   Gault, Victor A ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Glucagon like peptide 1 (GLP 1); Glucose dependent insulinotropic polypeptide (GIP); Insulin secretion; Obesity diabetes; Oxyntomodulin (OXM)

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; OXYNTOMODULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; CELL LINE; CRICETINAE; CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MOLECULAR SEQUENCE DATA; OXYNTOMODULIN; PEPTIDES; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; WEIGHT LOSS;

EID: 84877632331     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.03.009     Document Type: Article

References (32)

1. D.J. Drucker The biology of incretin hormones Cell Metab 3 2007 153 165
2. L.M. Morgan The metabolic role of GIP: physiology and pathology Biochem Soc Trans 24 1996 585 591
3. D.J. Drucker Biologic actions and therapeutic potential of the proglucagon-derived peptides Nat Clin Pract Endocrinol Metab 1 2005 22 31
4. E. Karra, and R.L. Batterham The role of gut hormones in the regulation of body weight and energy homeostasis Mol Cell Endocrinol 316 2010 120 128
5. C. Moss, W.S. Dhillo, G. Frost, and M. Hickson Gastrointestinal hormones: the regulation of appetite and the anorexia of ageing J Hum Nutr Diet 25 2012 3 15
6. C.F. Deacon, and B. Ahren Physiology of incretins in health and disease Rev Diabet Stud 8 2011 293 306
7. G. Tharakan, T. Tan, and S. Bloom Emerging therapies in the treatment of diabesity: beyond GLP-1 Trends Pharmacol Sci 32 2011 8 15
8. M.A. Cohen, S.M. Ellis, C.W. Le Roux, R.L. Batterham, A. Park, and M. Patterson Oxyntomodulin suppresses appetite and reduces food intake in humans J Clin Endocrinol Metab 88 2003 4696 4701
9. K. Wynne, A.J. Park, C.J. Small, K. Meeran, M.A. Ghatei, and G.S. Frost Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomized controlled trial Int J Obes (Lond) 30 2006 1729 1736
10. C.L. Dakin, C.J. Small, R.L. Batterham, N.M. Neary, M.A. Cohen, and M. Patterson Peripheral oxyntomodulin reduces food intake and body weight gain in rats Endocrinology 145 2004 2687 2695
11. A. Maida, J.A. Lovshin, L.L. Baggio, and D.J. Drucker The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances β-cell function but does not inhibit gastric emptying in mice Endocrinology 149 2008 5670 5678
12. B.D. Kerr, P.R. Flatt, and V.A. Gault (d-Ser(2))Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions Biochem Pharmacol 80 2010 1727 1735
13. J.W. Day, N. Ottaway, J.T. Patterson, V. Gelfanov, D. Smiley, and J. Gidda A new glucagon and GLP-1 co-agonist eliminates obesity in rodents Nat Chem Biol 5 2009 749 757
14. A. Pocai, P.E. Carrington, J.R. Adams, M. Wright, G. Eiermann, and L. Zhu GLP-1/GCGR dual agonism reverses obesity in mice Diabetes 58 2009 2258 2266
15. A. Pocai Unraveling oxyntomodulin, GLP-1's enigmatic brother J Endocrinol 215 2012 335 346
16. N. Irwin, P.R. Flatt, and V.A. Gault GIP-based therapeutics for diabetes and obesity Curr Chem Biol 2 2008 61 68
17. V.A. Gault, P.R. Flatt, and F.P. O'Harte Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes Biochem Biophys Res Commun 308 2003 207 213
18. S.A. Hinke, R.W. Gelling, R.A. Pederson, S. Manhart, C. Nian, and H.U. Demuth Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats Diabetes 51 2002 652 661
19. V.A. Gault, P.R. Flatt, C.J. Bailey, P. Harriott, B. Greer, and M.H. Mooney Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes Biochem J 367 2002 913 920
20. N.H. McClenaghan, C.R. Barnett, E. Ah-Sing, Y.H. Abdel-Wahab, F.P. O'Harte, and T.W. Yoon Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electro-fusion Diabetes 45 1996 1132 1140
21. S. Gremlich, A. Porret, E.H. Hani, D. Cherif, N. Vionnet, and P. Froguel Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor Diabetes 44 1995 1202 1208
22. B. Thorens, A. Porret, L. Buhler, S.P. Deng, P. Morel, and C. Widmann Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor Diabetes 42 1993 1678 1682
23. T. Ikegami, A.M. Cypess, and B. Bouscarel Modulation of glucagon receptor expression and response in transfected human embryonic kidney cells Am J Physiol Cell Physiol 281 2001 1396 1402
24. P.R. Flatt, and C.J. Bailey Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice Diabetologia 20 1981 573 577
25. C.J. Bailey The challenge of managing coexistent type 2 diabetes and obesity BMJ 342 2011 1 8
26. Y.M. Cho, C.E. Merchant, and T.J. Kieffer Targeting the glucagon receptor family for diabetes and obesity therapy Parmacol Ther 135 2012 247 278
27. V.A. Gault, B.D. Kerr, P. Harriott, and P.R. Flatt Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity Clin Sci (Lond) 121 2011 107 117
28. M.S. Islam, and R.D. Wilson Experimentally induced rodent models of type 2 diabetes Methods Mol Biol 933 2012 161 174
29. V.A. Gault, P.L. McClean, R.S. Cassidy, N. Irwin, and P.R. Flatt Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets Diabetologia 50 2007 1752 1762
30. C.F. Deacon, M.A. Nauck, J. Meier, K. Hucking, and J.J. Holst Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide J Clin Endocrinol Metab 85 2000 3575 3581
31. M.S. Fineman, K.F. Mace, M. Diamant, T. Darsow, B.B. Cirincione, and T.K. Booker Porter Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment Diabetes Obes Metab 14 2012 546 554
32. K. Aaboe, F.K. Knop, T. Vilsboll, A. Volund, U. Simonsen, and C.F. Deacon KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes J Clin Endocrinol Metab 94 2009 603 608